NL-OMON24266尚未招募不适用
RAdicale Cystectomy Evaluation. Comparative Effectiveness Study of Openversus Robot Assisted Laparoscopic Surgery
Rijnstate Hospital0 个研究点目标入组 338 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 338
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with non-metastatic muscle-invasive (cT2-T4a) and uncontrolled or highrisk
- •non Muscle-invasive bladder cancer (pTa-pT1)
排除标准
- •Extensive previous abdominal surgery
- •Abdominal irradiation
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.836
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-BEMerck Sharp & Dohme LLC608
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-DKMerck Sharp & Dohme LLC608
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.836
招募中
3 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with Muscle-Invasive Bladder CancerMuscle-invasive Bladder CancerJPRN-jRCT2031220686Koh Yasuhiro18